Stock ENBI ENTHEON BIOMEDICAL CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Entheon Biomedical Corp.

Equities

ENBI

CA29383X2023

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange
Other stock markets
 11:13:19 2024-04-29 am EDT 		5-day change 1st Jan Change
0.16 CAD 0.00% Intraday chart for Entheon Biomedical Corp. -20.00% +60.00%
Apr. 18 Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in funding CI
Apr. 11 Entheon Biomedical Corp. announced that it expects to receive CAD 0.1475 million in funding CI

Valuation

Fiscal Period: November 2020 2021 2022 2023
Capitalization 1 30.7 31.88 1.773 0.5909
Enterprise Value (EV) 1 27.86 29.83 1.093 0.2463
P/E ratio -4.76 x -3.3 x -0.21 x -1.97 x
Yield - - - -
Capitalization / Revenue - 1,471,213,659 x 9,345,767 x 2,360,518 x
EV / Revenue - 1,376,652,930 x 5,759,850 x 983,765 x
EV / EBITDA -17,007,259 x -3,288,893 x -308,369 x -
EV / FCF -14,371,381 x -13,929,199 x -641,929 x -978,084 x
FCF Yield -0% -0% -0% -0%
Price to Book 8.2 x 3.53 x 2.88 x 1.87 x
Nbr of stocks (in thousands) 4,039 5,904 5,909 5,909
Reference price 2 7.600 5.400 0.3000 0.1000
Announcement Date 3/30/21 3/30/22 3/23/23 3/26/24
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: November 2019 2020 2021 2022 2023
Net sales - - 0.0217 0.1897 0.2503
EBITDA - -1.638 -9.071 -3.543 -
EBIT 1 -0.6569 -1.641 -9.106 -3.6 -0.314
Operating Margin - - -42,022.39% -1,898.18% -125.43%
Earnings before Tax (EBT) 1 -0.6673 -4.381 -8.887 -2.061 -0.3
Net income 1 -0.6673 -4.381 -8.887 -8.521 -0.3
Net margin - - -41,008.56% -4,492.23% -119.85%
EPS 2 -5.040 -1.597 -1.637 -1.442 -0.0508
Free Cash Flow - -1.938 -2.142 -1.702 -0.2518
FCF margin - - -9,883.22% -897.27% -100.58%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 11/11/20 3/30/21 3/30/22 3/23/23 3/26/24
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: November 2019 2020 2021 2022 2023
Net Debt 1 - - - - -
Net Cash position 1 0.11 2.84 2.05 0.68 0.34
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - -1.94 -2.14 -1.7 -0.25
ROE (net income / shareholders' equity) - -231% -139% -42.7% -64.5%
ROA (Net income/ Total Assets) - -44.5% -78.8% -41.9% -33.5%
Assets 1 - 9.848 11.28 20.35 0.8945
Book Value Per Share 2 0.0200 0.9300 1.530 0.1000 0.0500
Cash Flow per Share 2 0.0500 0.6900 0.3500 0.1200 0.0600
Capex - 0.01 0.1 - -
Capex / Sales - - 452.1% - -
Announcement Date 11/11/20 3/30/21 3/30/22 3/23/23 3/26/24
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ENTHEON BIOMEDICAL CORP. Stock Entheon Biomedical Corp.
+60.00% 1.04M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.77% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+12.24% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-8.83% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.44% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.01% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.56% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.82% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ENBI Stock
  4. Financials Entheon Biomedical Corp.